Clinical trials: Multiple Sclerosis (MS) Relapsing Remitting
Multiple Sclerosis
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and…
- Trial name
- NCT00819195
- Testing
- Glatiramer acetate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Multiple Sclerosis, Relapsing-Remitting
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
This is an exploratory study, which allows analysis of multiple immune parameters derived from peripheral blood mononuclear cells (PBMCs) from patients with relapsing remitting multiple sclerosis before and during…
- Trial name
- DIMAT-MS (NCT02461069)
- Testing
- Dimethyl fumarate
- Where
- 6 sites in Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Relapsing Remitting Multiple Sclerosis, Fatigue
Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients
The main purpose of the study is to assess the fatigue, cognition, quality of life and disability correlation to MS-patients daily physical activity.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Fatigue, Quality of Life, Physical Activity
- Trial name
- PAMS (NCT04115930)
- Testing
- Physical Activity measurement:
- Where
- 4 sites in Finland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Multiple Sclerosis
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT01767493
- Testing
- [18F]Florbetapir PET imaging
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Relapsing-Remitting Multiple Sclerosis
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00391352
- Testing
- IFN-β-1a (Rebif®)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Waukesha Memorial Hospital
Multiple Sclerosis, Relapsing-Remitting
Cognition and MRI Markers in MS Patients With Aubagio® Treatment
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease which contributes largely to disability.
- Trial name
- AUBACOG (NCT03768648)
- Testing
- Clinical assessment, Ecological evaluation, Neuropsychological evaluation
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Relapsing Remitting Multiple Sclerosis
Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)
People with multiple sclerosis (MS) often experience problems with cognitive functioning, which can be debilitating and interfere with their daily functioning.
- Trial name
- NCT00914758
- Where
- 7 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Washington Neuropsychology Research Group
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04448977
- Testing
- Ocrevus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis, RRMS
Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy.
- Conditions
- Multiple Sclerosis, RRMS, Relapsing Remitting MS
- Trial name
- MIIMS (NCT07510607)
- Testing
- HP 13C pyruvate injection, MRI Scanner
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ari Green
Relapsing Remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis
Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis
Noninvasive brain stimulations (NIBS) will be used in MS patients with cognitive impairments to enhance their cognitive aptitudes.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Cognitive Deficits, Motor Deficits
- Trial name
- MScog-tDCS (NCT02266121)
- Testing
- tDCS
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital of Mont-Godinne
Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity.
- Conditions
- Multiple Sclerosis, Remitting-Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis
- Trial name
- NCT07426991
- Testing
- No Intervention: Observational Cohort
- Where
- 2 sites in Germany
- Volunteers
- 837 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis (MS) - Relapsing-remitting
Deuterium Metabolic Imaging in People with Multiple Sclerosis
The goal of this case-control study is to investigate glucose brain metabolism in people with multiple sclerosis and age- and sex-matched healthy controls.
- Trial name
- NCT06611280
- Testing
- No Interventions
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Multiple Sclerosis, Relapsing-Remitting
Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.
HLA-DRB1 * Gene and some genes involved in inflammation and immunity (IL-7R, GPC5, CTSS) have been linked to risk of MS and the response to treatment with immunomodulators.
- Trial name
- WESTEMDRB1 (NCT02769767)
- Testing
- Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Instituto Jalisciense de Cancerologia
Relapsing Remitting Multiple Sclerosis
Mechanistic Studies of Teriflunomide in RRMS
This study is to address the mechanism of action of teriflunomide in a phase IV open label trial with Teriflunomide in multiple sclerosis.
- Trial name
- NCT03464448
- Testing
- Teriflunomide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Multiple Sclerosis
Cognitive Effects of Immunomodulatory Drugs in MS
The purpose of this study is to examine and compare changes in the specific thinking skills of patients with RRMS who are receiving treatment with one of three immunomodulatory medications (Avonex, Copaxone, or Rebif).
- Trial name
- NCT00229502
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sharon Lynch, MD
Multiple Sclerosis (MS) - Relapsing-remitting
Educational Programs Based on Healthy Habits to Improve Quality of Life and Psychosocial Profile in Women With Neurodegenerative Diseases: The ADVICE Protocol Study (Phase 1)
This phase of the project aims to analyze the interaction between physical exercise and the phases of the menstrual cycle, evaluating its impact on fatigue, functional capacity, and exercise perception in women with and without…
- Trial name
- ADVICE Phase 1 (NCT06925022)
- Testing
- Strength training session during Early Follicular Phase, Strength Training Protocol during Late Follicular Phase, Strength Training during Mid-Luteal Phase
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidad de Almeria
Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis
PET with [18F]Flumazenil As an Index of Neurodegeneration in MS
Beyond white matter pathology, grey matter damage is considered as a key player in disability onset and progression in Multiple Sclerosis (MS).
- Trial name
- FLUMA-SEP-T (NCT03825601)
- Testing
- PET with [11C]Flumazenil
- Where
- France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Sclerosis
Gene Expression Profiles in Multiple Sclerosis (MS)
The purpose of this study is to test differences in RNA levels between Multiple Sclerosis (MS) patients and normal subjects. RNA provides a "message" from genes altered in diseases.
- Trial name
- NCT00704834
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Imaging of Intracerebral Inflammation in MS
In this study we plan to image the compartmentalized inflammation in MS using molecular imaging by positron emission tomography (PET) with a very highly resolutive camera.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- INFLASEP (NCT02305264)
- Testing
- 18F-DPA-714 and 18F-FDG
- Where
- 2 sites in France
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris